A close connection between research and the clinic
NIBR takes a unique approach to pharmaceutical research. At the earliest stages, research priorities are determined by patient need and disease understanding.
- At NIBR, physician-scientists are breaking down the boundaries between research and clinical practice.
- We use Proof-of-Concept clinical trials (small-scale studies used to get an early read on a drug’s safety and effectiveness) to help us to find and advance the most promising drug candidates.
- We believe we can better answer the demand for safer, more effective medicines by keeping our sights on both the science and the patient.
The key is cross-functional teamwork
Our model of research – connecting the laboratory to the clinic, and pursuing molecular pathways across a landscape of multiple diseases – means that we have to be a highly collaborative organization.
Every project is made up of cross-functional teams, drawn from
clinicians and more.
It is a way of working that has become a part of our research culture.
Novartis is a global collaborator of choice for biotechnology companies and academic centers.
New Psoriasis Treatment is More Than Skin Deep
The discovery of a potential new psoriasis treatment illustrates the NIBR approach.
Muckle Wells and Beyond
Novartis considers foremost which patients, not markets, are in greatest need of our medicines.